Literature DB >> 15001333

Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase.

Peter J Barnes1, Kazuhiro Ito, Ian M Adcock.   

Abstract

By contrast with patients with asthma, those with chronic obstructive pulmonary disease (COPD) are poorly responsive to the anti-inflammatory actions of corticosteroids, and these drugs provide little clinical benefit. In both diseases, multiple inflammatory genes are activated, which results from acetylation of core histones around which DNA is wound. This acetylation opens up the chromatin structure allowing gene transcription and synthesis of inflammatory proteins to proceed. Corticosteroids recruit histone deacetylase 2 (HDAC2) to the actively transcribing gene, which reverses this process and switches off inflammatory gene transcription. We propose that in patients with COPD, HDAC2 function is impaired by cigarette smoking and oxidative stress, leading to a pronounced reduction in responsiveness to corticosteroids. Oxidative stress could generate peroxynitrite, which impairs HDAC2 activity through nitration of critical tyrosine residues. This hypothesis raises the possibility that novel therapeutic approaches might unlock this corticosteroid resistance, leading to more effective anti-inflammatory treatments for COPD and other severe inflammatory diseases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15001333     DOI: 10.1016/S0140-6736(04)15650-X

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  86 in total

Review 1.  Histone modifications and alcohol-induced liver disease: are altered nutrients the missing link?

Authors:  Akshata Moghe; Swati Joshi-Barve; Smita Ghare; Leila Gobejishvili; Irina Kirpich; Craig J McClain; Shirish Barve
Journal:  World J Gastroenterol       Date:  2011-05-28       Impact factor: 5.742

2.  The tobacco smoke component acrolein induces glucocorticoid resistant gene expression via inhibition of histone deacetylase.

Authors:  Matthew J Randall; Guido R M M Haenen; Freek G Bouwman; Albert van der Vliet; Aalt Bast
Journal:  Toxicol Lett       Date:  2015-10-19       Impact factor: 4.372

3.  Theophylline for COPD.

Authors:  P J Barnes
Journal:  Thorax       Date:  2006-09       Impact factor: 9.139

4.  The efficacy and safety of cilomilast in COPD. Forward.

Authors:  Alvar Agusti
Journal:  Drugs       Date:  2008       Impact factor: 9.546

5.  Irreversible airway obstruction in asthma.

Authors:  Louis-Philippe Boulet
Journal:  Curr Allergy Asthma Rep       Date:  2009-03       Impact factor: 4.806

Review 6.  Thymic Germinal Centers and Corticosteroids in Myasthenia Gravis: an Immunopathological Study in 1035 Cases and a Critical Review.

Authors:  Frédérique Truffault; Vincent de Montpreville; Bruno Eymard; Tarek Sharshar; Rozen Le Panse; Sonia Berrih-Aknin
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

7.  Lung function decline in asthma: association with inhaled corticosteroids, smoking and sex.

Authors:  A Dijkstra; J M Vonk; H Jongepier; G H Koppelman; J P Schouten; N H T ten Hacken; W Timens; D S Postma
Journal:  Thorax       Date:  2005-11-24       Impact factor: 9.139

8.  Peripheral blood IRF1 expression as a marker for glucocorticoid sensitivity.

Authors:  William J Chapin; Divya Lenkala; Yifeng Mai; Yushan Mao; Steven R White; Rong S Huang
Journal:  Pharmacogenet Genomics       Date:  2015-03       Impact factor: 2.089

Review 9.  Inhaled corticosteroids in chronic obstructive pulmonary disease: a pro-con perspective.

Authors:  K Suresh Babu; Jack A Kastelik; Jaymin B Morjaria
Journal:  Br J Clin Pharmacol       Date:  2014-08       Impact factor: 4.335

Review 10.  Biological targets for therapeutic interventions in COPD: clinical potential.

Authors:  Girolamo Pelaia; Alessandro Vatrella; Luca Gallelli; Teresa Renda; Mario Caputi; Rosario Maselli; Serafino A Marsico
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.